- Optimi Health (OPTI) successfully completed its first batch of psilocybin cubensis and functional mushrooms
- With the vast availability of Optimi’s recently acquired genetics and the amendment to its Health Canada Dealer’s License, Optimi is positioned to lead the industry in the scalable cultivation of mushrooms
- Optimi Health engages in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector
- Optimi Health Corp. (OPTI) was up 11.11 per cent, trading at C$0.25 per share at 12:10 pm ET
Optimi Health (OPTI) successfully completed its first batch of psilocybin cubensis and functional mushrooms.
With the vast availability of Optimi’s recently acquired genetics and the amendment to its Health Canada Dealer’s License, Optimi is positioned to lead the industry in the scalable cultivation of mushrooms. It is ready to deliver on the company’s promise of building a future where natural psychedelic alternatives aid a wide variety of mental health conditions.
Bill Ciprick, CEO of Optimi commented on the announcement.
“It has been an amazing two-year journey getting to where we are today. Having now cultivated our first grow of psilocybin and functional mushrooms to a GMP standard, we are excited to be at full operational capacity and will proceed with domestic and international supply agreements with drug development companies and patients through the Special Access Program (SAP).”
Ciprick credits the company’s success on the work of Optimi Chief Science Officer, Justin Kirkland, and new Head of Cultivation, Todd Henderson.
Henderson supervised the eight-week cultivation process at the Company’s 20,000 square foot, technologically scaled EU-GMP grow facilities in Princeton, British Columbia. He will be giving public tours of his work at Optimi’s Grand Opening celebration on May 27.
Optimi Health engages in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products.
Optimi Health Corp. (OPTI) was up 11.11 per cent, trading at C$0.25 per share at 12:10 pm ET.
